Altimmune Inc (NASDAQ:ALT)’s Stock Is Sell After More Market Selling

April 17, 2018 - By Migdalia James

The stock of Altimmune Inc (NASDAQ:ALT) registered an increase of 23.51% in short interest. ALT’s total short interest was 975,500 shares in April as published by FINRA. Its up 23.51% from 789,800 shares, reported previously. With 363,200 shares average volume, it will take short sellers 3 days to cover their ALT’s short positions. The short interest to Altimmune Inc’s float is 11.07%.

The stock decreased 6.70% or $0.06 during the last trading session, reaching $0.78. About 510,139 shares traded or 85.73% up from the average. Altimmune, Inc. (NASDAQ:ALT) has declined 84.57% since April 17, 2017 and is downtrending. It has underperformed by 96.12% the S&P500.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $14.12 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

Altimmune, Inc. (NASDAQ:ALT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.